Cargando…

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018

Detalles Bibliográficos
Autores principales:	Brink, Mirian, Visser, Otto, Zweegman, Sonja, Sonneveld, Pieter, Broyl, Annemiek, van de Donk, Niels W.C.J., Dinmohamed, Avinash G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873037/ https://www.ncbi.nlm.nih.gov/pubmed/33563890 http://dx.doi.org/10.1038/s41408-021-00415-5

Ejemplares similares

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
por: Amaador, Karima, et al.
Publicado: (2021)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands
por: Slot, Stefanie, et al.
Publicado: (2021)

Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
por: Maas, Carolien C. H. M., et al.
Publicado: (2021)

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
por: van der Straten, Lina, et al.
Publicado: (2022)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
por: Wester, Ruth, et al.
Publicado: (2022)

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
por: van der Straten, Lina, et al.
Publicado: (2023)

OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
por: Tahri, Sabrin, et al.
Publicado: (2022)

Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
por: Durmaz, Müjde, et al.
Publicado: (2022)

Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
por: Maas, Carolien C.H.M., et al.
Publicado: (2023)

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002–2015
por: Dinmohamed, Avinash G., et al.
Publicado: (2018)

PB1886: LONG-TERM TRENDS IN THE LOSS OF LIFE EXPECTANCY AFTER A DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018
por: Van Der Straten, L., et al.
Publicado: (2022)

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands
por: Dinmohamed, Avinash G, et al.
Publicado: (2020)

Relative survival in early-stage cancers in the Netherlands: a population-based study
por: Dinmohamed, Avinash G., et al.
Publicado: (2020)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

Conditional relative survival in primary central nervous system lymphoma: a population-based study in the Netherlands
por: Dinmohamed, Avinash G, et al.
Publicado: (2020)

Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands
por: Posthuma, Hidde L. A., et al.
Publicado: (2021)

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
por: Wester, Ruth, et al.
Publicado: (2019)

Conditional relative survival in Waldenström’s macroglobulinaemia: a population‐based study in The Netherlands
por: Amaador, Karima, et al.
Publicado: (2021)

Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016
por: Posthuma, Hidde L. A., et al.
Publicado: (2019)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
por: Wester, Ruth, et al.
Publicado: (2020)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
por: van der Meulen, Matthijs, et al.
Publicado: (2020)

Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands
por: van der Straten, Lina, et al.
Publicado: (2021)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands
por: Dinnessen, Manette A. W., et al.
Publicado: (2021)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
por: Groen, Kaz, et al.
Publicado: (2023)

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, Kaz, et al.
Publicado: (2023)

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
por: Fokkema, Cathelijne, et al.
Publicado: (2022)

Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989–2003
por: van Blankenstein, M, et al.
Publicado: (2007)

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands
por: Dinmohamed, Avinash G., et al.
Publicado: (2020)

1989 CERN - JINR School of Physics: Egmond aan Zee, The Netherlands 25 Jun - 8 Jul 1989
por: CERN. Geneva
Publicado: (1991)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Smits, F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kovcfrjr287ma2j0p0gh3mdn12